Cilostazol is contraindicated in: Patients with congestive heart failure of any severity. Cilostazol and several of its metabolites are phosphodiesterase III inhibitors. Several drugs with this pharmacologic effect have caused decreased survival compared to placebo in patients with class III to IV congestive heart failure.
Patients with known or suspected hypersensitivity to any of its components.
Patients with any known predisposition to bleeding such as active peptic ulceration, hemorrhagic stroke within the last six months, proliferative diabetic retinopathy, poorly controlled hypertension.
Patients with any history of ventricular tachycardia, ventricular fibrillation or multifocal ventricular ectopics, whether or not adequately treated.
Patients with prolongation of the QTc interval.
Patients with history of severe tachyarrhythmia.
Patients with unstable angina pectoris, myocardial infarction/coronary intervention within the last six months.
Patients treated concomitantly with two or more additional antiplatelet or anticoagulant agents (e.g., aspirin, clopidogrel, heparin, warfarin, acenocoumarol, dabigatran, rivaroxaban or apixaban).